Deeks Emma D, Perry Caroline M
Wolters Kluwer Health, Adis, Auckland, New Zealand.
Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007.
Zoledronic acid (Aclasta; Reclast), a third-generation nitrogen-containing bisphosphonate, is the first once-yearly treatment to have been approved for use in patients with postmenopausal osteoporosis or at high risk of fracture. Intravenous zoledronic acid 5 mg once yearly is effective in reducing the risk of several types of fracture in patients with postmenopausal osteoporosis or recent low-trauma hip fracture. Moreover, improvements in bone mineral density (BMD) and reductions in markers of bone turnover are also generally observed. Zoledronic acid is generally well tolerated. Additional comparative data are required to definitively position zoledronic acid with respect to other agents. In the meantime, intravenous zoledronic acid 5 mg once yearly is a convenient and effective treatment option that may have an advantage over some other agents, for which adherence to treatment regimens is a recognized problem.
唑来膦酸（密固达；瑞舒伐）是第三代含氮双膦酸盐，是首个获批用于治疗绝经后骨质疏松症患者或骨折高风险患者的每年一次用药。每年静脉注射一次5毫克唑来膦酸，可有效降低绝经后骨质疏松症患者或近期低创伤性髋部骨折患者发生多种类型骨折的风险。此外，通常还可观察到骨矿物质密度（BMD）的改善以及骨转换标志物的降低。唑来膦酸一般耐受性良好。需要更多比较数据来明确唑来膦酸相对于其他药物的地位。与此同时，每年静脉注射一次5毫克唑来膦酸是一种方便有效的治疗选择，相对于其他一些药物可能具有优势，因为其他药物的治疗方案依从性是一个公认的问题。
